MONITORING LYMPHOCYTES PHENOTYPE DURING T101/ITRIUM THERAPY

T101/ITRIUM 治疗期间监测淋巴细胞表型

• 批准号: 3874352
• 负责人: T A FLEISHER
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3874352
• 关键词: T lymphocyte; cell population study; flow cytometry; human subject; leukemia; lymphocyte; lymphoma; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide therapy; peripheral blood vessel; tumor antigens; yttrium

Patients with T cell and B cell lymphoreticular malignancies bearing the cell surface antigen CDS will be evaluated prior to monoclonal antibody therapy to confirm the reported tumor cell findings. The peripheral blood lymphoid cells will then be immunophenotyped by flow cytometry and the phenotype will be monitored prior to and at intervals immediately post monoclonal antibody therapy. Particular attention to be paid to the lymphoid population distribution and the status of CDS. The patients are then studied daily for one week, weekly for the next month, and then periodically after that time.

患有T细胞和B细胞淋巴网状细胞恶性肿瘤的患者， 细胞表面抗原CDS将在单克隆抗体之前进行评价 治疗，以确认报告的肿瘤细胞结果。外周血 然后通过流式细胞术对淋巴细胞进行免疫表型分析，并 将在给药前和给药后立即监测表型 单克隆抗体治疗应特别注意 淋巴样群体分布和CDS的状态。病人 然后每天学习一周，下个月每周学习一次， 在此之后定期。